Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer

[1]  J. Silber,et al.  Multilineage plasticity in prostate cancer through expansion of stem–like luminal epithelial cells with elevated inflammatory signaling , 2021 .

[2]  M. Loda,et al.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer , 2021, Nature Communications.

[3]  X. Qiu,et al.  Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases , 2021, Frontiers in Oncology.

[4]  H. Beltran,et al.  Clinical and Biological Features of Neuroendocrine Prostate Cancer , 2021, Current Oncology Reports.

[5]  Charlotte Soneson,et al.  CellMixS: quantifying and visualizing batch effects in single-cell RNA-seq data , 2020, Life Science Alliance.

[6]  Henry W. Long,et al.  Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer , 2020, Nature Communications.

[7]  Annelisa M Cornel,et al.  MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy , 2020, Cancers.

[8]  Y. Saeys,et al.  A scalable SCENIC workflow for single-cell gene regulatory network analysis , 2020, Nature Protocols.

[9]  Nakul M. Shah,et al.  A genomic and epigenomic atlas of prostate cancer in Asian populations , 2020, Nature.

[10]  J. Fraser,et al.  hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen , 2019, Scientific Reports.

[11]  O. Elemento,et al.  Clinical features of neuroendocrine prostate cancer. , 2019, European journal of cancer.

[12]  Christina S. Leslie,et al.  FOXA1 mutations alter pioneering activity, differentiation, and prostate cancer phenotypes , 2019, Nature.

[13]  Henry W. Long,et al.  Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors , 2019, Nature Medicine.

[14]  Jun Zhu,et al.  Epigenomic profiling discovers trans-lineage SOX2 partnerships driving tumor heterogeneity in lung squamous cell carcinoma. , 2019, Cancer research.

[15]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[16]  Andrew J. Hill,et al.  The single cell transcriptional landscape of mammalian organogenesis , 2019, Nature.

[17]  T. Graeber,et al.  Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage , 2018, Science.

[18]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Michael D. Nyquist,et al.  Abstract LB-199: Role of ASCL1 in neuroendocrine prostate cancer progression , 2018, Molecular and Cellular Biology / Genetics.

[20]  Pardis C Sabeti,et al.  Identifying gene expression programs of cell-type identity and cellular activity with single-cell RNA-Seq , 2018, bioRxiv.

[21]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[22]  T. Hughes,et al.  The Human Transcription Factors , 2018, Cell.

[23]  S. Fine.  Neuroendocrine tumors of the prostate , 2018, Modern Pathology.

[24]  Jiaoti Huang,et al.  FOXA2 is a Sensitive and Specific marker for Small Cell Neuroendocrine Carcinoma of the Prostate , 2017, Modern Pathology.

[25]  M. Rubin,et al.  Biology and evolution of poorly differentiated neuroendocrine tumors , 2017, Nature Medicine.

[26]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[27]  Joshua M. Stuart,et al.  N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. , 2016, Cancer cell.

[28]  R. Montironi,et al.  Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification , 2016, Endocrine Pathology.

[29]  R. Elkon,et al.  Redifferentiation of expanded human islet β cells by inhibition of ARX , 2016, Scientific Reports.

[30]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[31]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[32]  Robert H. Bell,et al.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. , 2015, Cell reports.

[33]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[34]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[35]  M. Rubin,et al.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.

[36]  C. Rudin,et al.  Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. , 2013, Journal of the National Cancer Institute.

[37]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[38]  M. Rots,et al.  EpCAM in carcinogenesis: the good, the bad or the ugly. , 2010, Carcinogenesis.

[39]  R. Goldman,et al.  Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  I. Mills,et al.  Pro-neural transcription factors as cancer markers , 2008, BMC Medical Genomics.

[41]  I. Kirov,et al.  Expression of Neurodevelopmental Markers by Cultured Porcine Neural Precursor Cells , 2005, Stem cells.

[42]  H. Moch,et al.  Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. , 1998, The Journal of urology.

[43]  T. H. van der Kwast,et al.  The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.

[44]  C. Murre,et al.  Localization of Pbx1 transcripts in developing rat embryos , 1995, Mechanisms of Development.

[45]  C. Cordon-Cardo,et al.  Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. , 1994, The Journal of urology.

[46]  F. Johnson,et al.  Small cell carcinoma of the prostate , 1991, Cancer.

[47]  R. Wenk,et al.  Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia , 1977, Cancer.

[48]  M. Rubin,et al.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. , 2017, Cancer discovery.

[49]  B. Czerniak,et al.  TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. , 2011, Human pathology.

[50]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[51]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications , 1992, Cancer.

[52]  A. DeMaria,et al.  Diagnostic, Prognostic and Therapeutic Implications , 1974 .